cancer

The drug, in combination with chemotherapy, helped patients with advanced colorectal cancer live significantly longer.

Details will be released at an upcoming medical meeting. Regeneron is developing the product with drug giant Sanofi-Aventis (NYSE:SNY).

The companies said they hope to file for U.S.

Regeneron Pharmaceuticals (NASDAQ:REGN) soared over 40% at one point Wednesday afternoon, after the company reported positive results from a Phase III study for its drug Zaltrap.

Kevin Buchi, Chief Executive Officer of Cephalon, said, "The proposed transaction allows ChemGenex shareholders to realize cash proceeds at a significant premium to recent trading levels and adds an interesting late-stage opportun

The deal will give the company a potential leukemia treatment and is Cephalon's seventh acquisition in the past year.

Cephalon Inc. (NASDAQ:CEPH) agreed to buy ChemGenex Pharmaceuticals Ltd. for A$225 million in cash, according to a Bloomberg report.

Aflac (AFL) also has investment exposure to the giant utility that operates the power stations that were damaged by Friday's massive earthquake, according Marketwatch.

Aflac (AFL) loses ground on concern about possible radiation leaks from Japanese nuclear reactors and how they might affect the largest seller of cancer insurance in the country, Marketwatch.com reports late Monday.

Dr. Barry Polisky, Chief Scientific Officer at Marina, said in a statement: "These results further demonstrate the utility of our DiLA2 delivery technology for local administration."

Marina Biotech shares are up 7.47%, to $0.731.

Shares of Marina Biotech (MRNA) are higher after company data was presented demonstrating significant knockdown of target mRNA in an orthotopic model of malignant ascites with its proprietary UsiRNA construct and DiLA2-based deliv

Revenue for the quarter was $25 million, compared to $21,000 for the same quarter in 2009. FY revenue came in at $48.1 million, compared to $100,000 the year before.

Mitchell H.

Dendreon (NASDAQ:DNDN) reported Q4 and FY 2010 earnings results Tuesday during the trading day, posting a disappointing loss of $0.64 per share for the quarter, a bigger loss than the $0.49 analysts were projecting on average. Net

Gilead Sciences (GILD) today announced that it has acquired Calistoga Pharmaceuticals, a privately held company, for $375 million. GILD stated that with the acquisition, it hopes to expand its research capabilities into cancer dru

Under the contract, Astellas will pay AVEO $575 million once the treatment is approved by regulators and $780 million or more once it meets certain sales targets. Both companies will share costs and profits from sales of the drug

AVEO Pharmaceuticals (AVEO) is up 8.07%, after Tokyo-based Astellas Pharma (TYO:4503) agreed purchase the rights to develop and sell the experimental cancer drug, tivozanib, for $1.3 billion, Bloomberg reported.

Technology shares are higher in mid-day trading while Autodesk (ADSK) shares decline after it announced that it has entered into a definitive agreement to acquire Blue Ridge Numerics, a leading provider of simulation software, for

President and Chief Executive Officer of Seattle Genetics, commented: "The strong brentuximab vedotin data we reported during the fourth quarter of 2010 highlighted an important year for Seattle Genetics, and position the company

Seattle Genetics (NASDAQ:SGEN) reported a Q4 loss of $0.34 per share, narrower than consensus estimates for a loss of $0.38 per share. Revenues for the quarter fell 63% year-over-year to $8.1 million, missing consensus estimates o